Every 10-Q that Lexeo Therapeutics, Inc. (LXEO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LXEO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LXEO filings page.
Lexeo Therapeutics, Inc., a clinical-stage genetic medicine company focused on AAV-based cardiovascular gene therapies, reported continued operating losses while maintaining a strong cash position for the quarter and six months ended June 30, 2026.
Total operating expenses were $28.0 million for the quarter and $50.4 million for the first half of 2026, down from $30.7 million and $64.5 million in the prior-year periods, driven mainly by lower general and administrative costs. Net loss was $25.9 million for the quarter and $46.1 million year-to-date, compared with $26.1 million and $58.8 million a year earlier. Net cash used in operating activities was $38.7 million for the first half of 2026.
Cash, cash equivalents and investments in U.S. Treasury securities totaled $234.2 million as of June 30, 2026, with total assets of $254.9 million and stockholders’ equity of $235.1 million. Management estimates these balances are sufficient to fund operations for at least 12 months from issuance of the financial statements, though the company expects to continue incurring substantial losses while advancing its gene therapy pipeline.
Lexeo Therapeutics’ quarterly report shows a smaller loss and a solid cash position as it advances gene therapy programs for cardiovascular disease. For the three months ended March 31, 2026, net loss was $20.2 million, improved from $32.7 million a year earlier, as operating expenses fell to $22.3 million from $33.8 million.
The company reported cash, cash equivalents and investments in U.S. Treasury securities of $227.6 million and total assets of $250.4 million, with an accumulated deficit of $400.3 million. Management believes this cash balance will fund operations for at least 12 months, though additional capital will be needed longer term.
Lexeo Therapeutics (LXEO) reported Q3 2025 results with a net loss of $20.3 million (basic and diluted $0.33 per share). Operating expenses were $21.6 million, driven by $15.7 million in research and development and $6.0 million in general and administrative costs. Other income reflected $1.5 million of interest income.
As of September 30, 2025, cash, cash equivalents and investments in U.S. Treasury securities totaled $122.8 million (cash and cash equivalents $41.0 million; current Treasuries $81.8 million). Management estimates these resources are sufficient to fund operations for at least 12 months from the issuance date. The company received net proceeds of $73.1 million from a May 2025 private placement during the period, and subsequently added $143.9 million of estimated net proceeds in October 2025 financing transactions. An at-the-market program for up to $75.0 million was in place with no sales through quarter end. Shares outstanding were 72,987,327 as of November 3, 2025.
Lexeo Therapeutics reported financial and clinical updates for the period ended June 30, 2025. The company holds approximately $152.5 million in cash, cash equivalents and U.S. Treasury securities and an accumulated deficit of $338.9 million. Net loss for the six months was $58.8 million, driven by total operating expenses of $64.5 million year-to-date, with general and administrative costs rising notably versus the prior year.
Liquidity was strengthened by a May 2025 private placement that raised gross proceeds of ~$80.0 million and net proceeds of $73.1 million, and management estimates current resources are sufficient to fund operations for at least 12 months. Clinically, Lexeo highlighted progress with LX2006 in Phase 1/2 and an investigator-initiated Cornell trial, reporting early improvements in cardiac biomarkers and measurable increases in cardiac frataxin protein in biopsies for some patients, generally well-tolerated aside from one transient Grade 2 asymptomatic myocarditis. The company has FDA alignment on a registrational plan using left ventricular mass index and frataxin protein expression as co-primary endpoints.